1093066-71-7

Basic information

• Product Name: 1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole
• Synonyms: 1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole;1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole-2;1-(tert-butyldimethylsilyl)-5-fluoro-1H-indole
• CAS NO: 1093066-71-7
• Molecular Formula: C14H20FNSi
• Molecular Weight: 249
• Mol File: 1093066-71-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole(1093066-71-7)
• EPA Substance Registry System: 1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole(1093066-71-7)

Safety Data

• Hazardous Substances Data: 1093066-71-7(Hazardous Substances Data)

Usage

Chemical structure

1-(tert-butyl-dimethyl-silanyl)-5-fluoro-1H-indole is a compound with a fluoro-substituted indole ring and a tert-butyl-dimethyl-silanyl group attached to the nitrogen.

Functional groups

The compound contains an indole ring, a fluorine atom, a tert-butyl group, and a dimethyl-silanyl group.

Steric hindrance

The tert-butyl-dimethyl-silanyl group provides steric hindrance, which can be useful for selective transformations and as a directing group in organic synthesis.

Protection of nitrogen atom

The tert-butyl-dimethyl-silanyl group also protects the nitrogen atom, making the compound more stable and less reactive.

Fluorine substitution

The presence of a fluorine atom on the indole ring may confer specific biological properties in potential drug candidates.

Applications

The compound is commonly used in research and pharmaceutical development as a building block for the synthesis of various biologically active molecules.

Potential in medicinal chemistry

Due to its unique structure and properties, the compound has potential applications in medicinal chemistry and drug discovery.

Biological activity

The specific biological properties conferred by the fluorine substitution on the indole ring may make the compound a valuable tool in the development of new drugs and therapies.

Upstream product

• 399-52-0 5-fluoro-1H-indole 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1093066-72-8 [1-(tert-butyldimethylsilanyl)-5-fluoro-1H-indol-4-yl]boronic acid 
• 1148004-02-7 5-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tert-butyldimethylsilylindole 
• 1449580-83-9 2-(5-fluoro-1H-indol-4-yl)-5-[4-(3,3-dimethylpiperazin-1-yl)phenyl]-1,3-oxazole-4-carboxylic acid amide 

Relevant articles and documents

Discovery of novel PI3-Kinase δ specific inhibitors for the treatment of rheumatoid arthritis: Taming CYP3A4 time-dependent inhibition

PI3Kδis a lipid kinase and a member of a larger family of enzymes, PI3K class IA(α, β, δ) and IB (γ), which catalyze the phosphorylation of PIP2 to PIP3. PI3Kδ is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive opportunity to treat diseases where B cell activity is essential, e.g., rheumatoid arthritis. We report the discovery of novel, potent, and selective PI3Kδinhibitors and describe a structural hypothesis for isoform (α, β γ?) selectivity gained from interactions in the affinity pocket. The critical component of our initial pharmacophore for isoform selectivity was strongly associated with CYP3A4 time-dependent inhibition (TDI). We describe a variety of strategies and methods for monitoring and attenuating TDI. Ultimately, a structure-based design approach was employed to identify a suitable structural replacement for further optimization.

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1): and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.

THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.